Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma

Archives of Ophthalmology

Volumn 126, Issue 7, 2008, Pages 953-958

  Lee, Sun Young ^a   Kim, Dong Kyu ^a   Cho, Jae Hyung ^a   Koh, Joe Young ^a   Yoon, Young Hee ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; TUMOR GROWTH; TUMOR VOLUME; UMBILICAL VEIN; XENOGRAFT; XENOTRANSPLANTATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; CELL PROLIFERATION; COCULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MICROSCOPY, PHASE-CONTRAST; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RETINAL NEOPLASMS; RETINOBLASTOMA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47549084965     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.7.953     Document Type: Article

References (38)

1. Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol. 1975;80(2):263-265.
2. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990;108(1):128-132.
3. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control. 2004;11(5):317-327.
4. Shields JA, Shields CL. Current management of retinoblastoma. Mayo Clin Proc. 1994;69(1):50-56.
5. Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene. 2006;25(38):5341-5349.
6. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105(4):573-579.
7. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118(4):577-578.
8. Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol. 1976;16:207-248.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-364.
10. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
11. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis: introduction. Cancer Metastasis Rev. 1990;9(3):171-174.
12. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844.
13. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-4599.
14. Burnier MN, McLean IW, Zimmerman LE, Rosenberg SH. Retinoblastoma: the relationship of proliferating cells to blood vessels. Invest Ophthalmol Vis Sci. 1990;31(10):2037-2040.
15. Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63(5):511-518.
16. Pe'er J, Neufeld M, Baras M, et al. Rubeosis iridis in retinoblastoma: histologic findings and the possible role of vascular endothelial growth factor in its induction. Ophthalmology. 1997;104(8):1251-1258.
17. Stitt AW, Simpson DA, Boocock C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol. 1998;186(3):306-312.
18. The Institutional Animal Care and Use Commmittee (IACUC) Statement for the Use of Animals. Asan Institute for Life Sciences Web site. http://asanscience.re.kr. Accessed March 1, 2006.
19. Statement for the Use of Animals in Ophthalmic and Visual Research. The Association for Research in Vision and Ophthalmology (ARVO) Web site. http://www.arvo.org/eweb/dynamicpage.aspx?site=arvo2&webcode= AnimalsResearch. Accessed March 1, 2006.
20. Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett. 1997;117(1):93-98.
21. Chantrain CF, DeClerck YA, Groshen S, McNamara G. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem. 2003;51(2):151-158.
22. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.
23. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007;62(3):179-213.
24. Tapper D, Albert DM, Robinson NL, Zetter BR. Capillary endothelial cell migration: stimulating activity of aqueous humor from patients with ocular cancers. J Natl Cancer Inst. 1983;71(3):501-505.
25. Rössler J, Dietrich T, Pavlakovic H, et al. Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol. 2004;164(2):391-394.
26. Albert DM, Tapper D, Robinson NL, Felman R. Retinoblastoma and angiogenesis activity. Retina. 1984;4(3):189-194.
27. Jia RB, Zhang P, Zhou YX, et al. VEGF-targeted RNA interference suppresses an-giogenesis and tumor growth of retinoblastoma. Ophthalmic Res. 2007;39(2):108-115.
28. Rosenblatt MI, Azar DT. Anti-angiogenic therapy: prospects for treatment of ocular tumors. Semin Ophthalmol. 2006;21(3):151-160.
29. Bergsland EK. Update on clinical trials targeting vascular endothelial growth factor in cancer. Am J Health Syst Pharm. 2004;61(21)(suppl 5):S12-S20.
30. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27(4):439-444.
31. Scott IU, Edwards AR, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-1867.
32. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502-3508.
33. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res. 2005;11(6):2364-2378.
34. Segerström L, Fuchs D, Bäckman U, Holmquist K, Christofferson R, Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res. 2006;60(5):576-581.
35. Schweigerer L. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med. 1995;73(10):497-508.
36. Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol. 2005;16(1):7-15.
37. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem. 2006;13(16):1845-1857.
38. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH (BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006;47(4):1264-1268.